Abstract. Zinc finger and BTB domain-containing 7A (Zbtb7A) is a proto-oncogene overexpressed in numerous cancers. In this study, we explored the mechanism of insulin-induced Zbtb7A expression. Real-time PCR and western blotting were used to detect Zbtb7A expression. Zbtb7A promoter activity was monitored by Luciferase reporter assay. It was shown that insulin elevates the mRNA and protein levels of the Zbtb7A gene in HepG2 cells. Using chemical inhibitors of insulin downstream pathways, we demonstrated that the insulin-induced Zbtb7A gene expression was completely blocked by LY294002, a PI3K/AKT inhibitor, and partially attenuated by the MAPK inhibitor PD98059. Transfection of HepG2 cells with a 1 kb Zbtb7A promoter-luciferase reporter construct revealed a dose-dependent activation of the Zbtb7A promoter by insulin, while mutation of the Sp1 binding site within the Zbtb7A promoter resulted in the failure of insulin-induced promoter activation, suggesting that insulin increases Zbtb7A expression through transcriptional regulation mediated by Sp1 in HepG2 cells.
Introduction
Human zinc finger and BTB domain-containing 7A (Zbtb7A), also known as POK erythroid myeloid ontogenic factor (pokemon) (1) , factor that binds to IST, the HIV-1 inducer of short transcripts (FBI-1) (2), leukemia/lymphoma-related factor mouse homolog (LRF) (3) and osteoclast-derived zinc finger rat homolog (OCZF) (4), was originally identified as a cellular factor that binds specifically to the human immunodeficiency virus type 1 promoter element (5) . Zbtb7A belongs to the POK protein family (6) and plays critical roles in differentiation (7), oncogenesis (1, 8) and adipogenesis (9) . The overexpression of Zbtb7A is observed in various human cancers (1) . Zbtb7A suppresses the p14ARF, Rb tumor suppressor gene (1, 10) , p21CIP1 (11) , E2F4 and cyclin A (9) , indicating that Zbtb7A may be a molecular target for cancer therapy.
Many Zbtb7A downstream targets have been identified, but little is known about the mitogens that regulate the expression of Zbtb7A. Roh et al reported that Zbtb7A activity was regulated by sumoylation (12) . In addition, we have demonstrated previously that Sp1, a well-known effector of insulin in cancer cells (13) , elevates Zbtb7A expression by directly binding to its promoter (14) . Based on this study, we hypothesized that there is a correlation between insulin and Zbtb7A expression.
Apart from its role in the regulation of glucose uptake, insulin also acts as a mitogen and differentiation factor in a variety of cells and tissues (15) (16) (17) (18) . As a mitogen, insulin regulates the transcription of >100 genes (19, 20) and promotes cell growth (21, 22) . The actions of insulin are initiated through the activation of the insulin receptor, which is a receptor tyrosine kinase, and downstream serine/threonine kinase-signaling pathways including PI 3-kinase (PI3K/AKT) and Ras-MAPK cascades (23, 24) . Boyd reported that the bioavailability of insulin contributes to tumor development (25) . It has also been reported that insulin is able to stimulate the expression of the oncogene PTTG (26) . In the current study, we demonstrate that the mRNA and protein levels of Zbtb7A are significantly upregulated by insulin via the PI3K/AKT pathway and the transcription factor Sp1.
Materials and methods

Materials.
Insulin and polyclonal anti-Zbtb7A were obtained from Sigma (St. Louis, MO, USA). Goat anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody, goat anti-mouse HRP-linked antibody, the PI3K/AKT inhibitor LY294002 and the MAPK inhibitor PD98059 were purchased from Beyotime Biotech (Jiangsu, China). The nylon membrane Hybond-N was obtained from Pall Corporation (Port Washington, NY, USA). The TRIzol reagent was purchased from Invitrogen Life Technologies (Carslbad, CA, USA).
Cell culture. HepG2 cells were cultured in Dullbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin in humidified air containing 5% CO 2 at 37˚C. Cells were trypsinized and seeded in 6-well plates and grown to 50-70% confluence. They were then stimulated with various reagents as described in the figure legends.
RNA extraction and real-time PCR analysis. The total RNA of the HepG2 cells was isolated using TRIzol reagent. Reverse transcription was performed using a RT-PCR kit according to the instructions of the manufacturer (Toyobo, Osaka, Japan). The quantification of the Zbtb7A mRNA (1 µg) was performed using an ABI 7500 real-time PCR system with the Zbtb7A specific primers: 5'-GAAGCCCTACGAGTGCAACATC-3' (forward) and 5'-GTGGTTCTTCAGGTCGTAGTTGTG-3' (reverse). GAPDH served as the internal control and was amplified with the following primers: 5'-GGTGGTCTCCTCT GACTTCAACA-3' (forward) and 5'-GTTGCTGTAGCCAAA TTCGTTGT-3' (reverse). The volume of real-time RT-PCR system was 20 µl, containing: 10 µl SYBR-buffer, 0.4 µl forward primer (10 µmol/l), 0.4 µl reverse primer (10 µmol/l), 0.4 µl SYBR-Green Ⅱ dye, 1 µl cDNA and 7.8 µl water. Thermal cycling conditions were denaturation at 95˚C for 10 sec, and then 5 sec denaturation at 95˚C, 34 sec annealing at 60˚C for 40 cycles, followed by a dissociation stage (95˚C for 15 sec, 60˚C for 1 min and 95˚C for 15 sec) to monitor the specificity of the primers. All samples were run in triplicate.
Site directed mutagenesis. The Sp1 recognition site of the Zbtb7A promoter was GGGCGG, -641-636 bp relative to the transcription start site. The mutation of this site was obtained by preparing the mutated promoter Sp1M, using mutated primers within GC-boxes. The plasmids with mutation were generated using a site-directed mutagenesis system (Promega, Madison, WI, USA) according to the instructions provided by the manufacturer and a pLuc1000 construct was used as a template. The oligonucleotide used for mutagenesis (mutations indicated with inclined form and bold letters) is: 5'-AATGATCCAAAAAAAACTGCCTCCCAAG-3'. DNA sequencing was performed to confirm that the sequences of the PCR products were correct as compared with the Zbtb7A promoter published in the Human Genome database.
Plasmid transfection and luciferase assay. Human pGL4.10-Zbtb7A promoter pLuc1000 (1000 bp, wild-type) or mutated promoter Sp1M was used for transient transfection. Cells were plated in 24-well plates. After culturing for 18 h, the cells were transfected with Lipofectamine 2000 according to the instructions of the manufacturer (Invitrogen Life Technologies). Wild-type or mutated Zbtb7A promoter-luciferase construct (1 µg/well) was used and 30 ng/well of pRLTK plasmid was co-transfected as a control reporter plasmid. Six hours after transfection, the cells were washed with PBS twice, cultured in DMEM containing 10% FBS for 24 h and then treated with the indicated concentrations of insulin for 24 h.
Cells were harvested by lysis buffer (Promega). Cell lysates (10 µl) were analyzed to determine the promoter activity. Three independent transfection experiments were carried out for each assay.
Western blot analysis. Following treatment with the indicated reagents, the cells were lysed with RIPA buffer containing 10 mM KCl, 0.1% Nonidet P-40, 10 mM HEPES, pH 7.9, 1 mM ethylenediamine tetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM Na 3 VO 4 and 1 mM dithiothreitol (DTT). The protein concentration was determined by Bradford protein assay. Equal amounts of each protein sample (30 µg) were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. Blots were incubated in 5% non-fat milk at room temperature for 1 h, washed three times with 0.5% Tween-20 Tris-buffered saline (TBST) and probed with a suitable primary antibody at room temperature for 2 h. The membrane was washed and incubated with secondary antibody for 1 h at room temperature and detected using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). β-actin was used to monitor the equal loading of each sample.
Statistical analysis. Statistical analysis was performed using ANOVA. Values of * P<0.05, ** P<0.01 and *** P<0.001 were considered to indicate statistically significant differences.
Results
Insulin regulates Zbtb7A expression in a dose-dependent manner.
To determine whether insulin enhances Zbtb7A expression, HepG2 cells were treated with various concentrations of insulin or left untreated for 24 h. The Zbtb7A mRNA and protein levels were analyzed by real-time PCR and western blot analysis, respectively. As shown in Fig. 1 , insulin activated Zbtb7A expression in a dose-dependent manner. Compared with the control group, when the cells treated with 10, 50 and 100 nM insulin, the Zbtb7A mRNA levels were increased 1.21-, 1.45-(P<0.05) and 2.17-fold (P<0.01), respectively; similarly, the Zbtb7A protein levels were increased 1.47-, 1.49-and 2.09-fold (all P<0.05), respectively ( Fig. 1B and C) .
Insulin stimulates Zbtb7A expression in a time-dependent manner. We then sought to discover the time-dependent effects of insulin on Zbtb7A expression. HepG2 cells treated with 100 nM insulin were harvested at different time-points. It was found that the insulin-induced upregulation of Zbtb7A mRNA levels was time-dependent ( Fig. 2A) . The expression levels of Zbtb7A in the cells treated with 100 nM insulin for 6, 12 and 24 h were increased 1.38-(P<0.01), 2.01-(P<0.05) and 2.51-fold (P<0.05), respectively, compared with untreated cells. In addition, a maximum 2.09-fold (P<0.001) increase in Zbtb7A protein levels was observed 24 h after insulin treatment, but no marked changes in Zbtb7A protein levels were detected at 6 and 12 h (Fig. 2B and C) . These results suggest that insulin upregulates the mRNA and protein levels of Zbtb7A in HepG2 cells in a time-dependent manner.
Insulin-induced upregulation of Zbtb7A expression is mediated by the PI3K/AKT pathway. Insulin mediates target proteins through two major pathways: PI3K/AKT and MAPK. We used specific inhibitors of the two pathways to identify which of these pathways are involved in the insulin-induced Zbtb7A expression. HepG2 cells were pre-treated with LY294002 (a PI3K inhibitor) or PD98059 (a MAPK inhibitor) for 30 min, and then incubated with DMEM containing 100 nM insulin and the indicated inhibitors. It was identified that LY294002 completely blocked the insulin-induced Zbtb7A expression at the mRNA and protein levels, and that PD98059 partially attenuated the effect of insulin on Zbtb7A expression (Fig. 3) . The results indicate that insulin enhances Zbtb7A expression predominantly through the PI3K/AKT pathway.
Insulin enhances Zbtb7A promoter activity through Sp1.
To elucidate the mechanism of the insulin-induced Zbtb7A expression, wild-type and mutated Zbtb7A promoter-luciferase constructs were developed and transiently transfected into HepG2 cells prior to treatment of the cells with various concentrations of insulin. As shown in Fig. 4A , the activity of the Zbtb7A promoter was increased by insulin in a concentration-dependent manner. Insulin (100 nM) increased Zbtb7A promoter activity by 48.3% compared with the control group.
Since Sp1 is an effector that mediates the action of insulin on gene expression, we attempted to determine whether Sp1 plays a role in the insulin-induced Zbtb7A expression by using a wild-type promoter of Zbtb7A and an Sp1 binding site mutated promoter (Sp1M). Cells transfected with the wild-type or mutated promoters were treated with or without 100 nM insulin for 48 h. As shown in Fig. 4C , the activity of the wild-type promoter was enhanced by insulin, while Sp1M demonstrated no clear response to insulin treatment. Therefore, it may be inferred that insulin enhances Zbtb7A promoter activity through Sp1 binding sites.
Discussion
Our results demonstrate that insulin upregulates Zbtb7A expression in HepG2 cells. To our knowledge, this is the first report that insulin stimulates Zbtb7A promoter activity and enhances endogenous Zbtb7A mRNA and protein levels in a dose-and time-dependent manner, and that the PI3K/AKT cascade and transcription factor Sp1 are responsible for the insulin-induced Zbtb7A expression in HepG2 cells.
To validate the effect of insulin on Zbtb7A expression, we treated HepG2 cells with various concentrations of insulin for 24 h. Cells incubated with 100 nM insulin revealed a A A B B C C maximum 2.17-fold increase in the Zbtb7A mRNA level and a 2.09-fold increase in the Zbtb7A protein level. We then cultured the cells in DMEM with 100 nM insulin for various times, and tested the mRNA and protein levels of Zbtb7A at the indicated time-points. The highest Zbtb7A protein and mRNA levels were induced by insulin in the HepG2 cells at 24 h. Zbtb7A mRNA was elevated significantly at 6 and 12 h, however, the corresponding protein level showed no evident increase at these times. These differences may be due to the interval between gene transcription and mRNA translation. We used specific inhibitors of different insulin pathways to determine which pathway may be involved in the insulin-induced Zbtb7A expression. The observation that LY294002 completely blocked the insulin-induced Zbtb7A expression, while PD98059 attenuated the effect of insulin on Zbtb7A expression to a lesser extent than LY294002, suggests that insulin regulates Zbtb7A expression via the PI3K/AKT pathway. A 1-kb Zbtb7A promoter luciferase construct was developed to identify whether insulin has an effect on Zbtb7A gene promoter activity. The promoter activity was increased 1.48-fold by treatment with 100 nM insulin. However, insulin was not able to boost the activity of a Zbtb7A promoter with an Sp1 binding site mutation. These results suggest that insulin upregulates Zbtb7A mRNA synthesis through the activation of the Zbtb7A gene promoter via Sp1.
Insulin has the effect of modulating carbohydrate metabolism and regulating certain oncogenes, including c-myc and PTTG (26) (27) (28) (29) . Messina reported that insulin initially inhibits the proto-oncogene c-myc, but this initial decrease in c-myc is followed by an approximately 3-fold increase in c-myc expression by 60-120 min (27) . Thompson and Kakar demonstrated that insulin and IGF-1 stimulate the expression of the oncogene PTTG in a time-and dose-dependent manner through the PI3K/AKT pathway, and they also suggested that insulin-related signaling pathways are a potential molecular target for cancer therapy (26) . Since the increased expression of Zbtb7A in non-small cell lung cancer (NSCLC) resulted in carcinogenesis and Zbtb7A had some clinical significance for the prognostic evaluation of patients with NSCLC (30), the stimulation of Zbtb7A by insulin provides a possible mechanism by which insulin contributes to tumor development and/or progression.
Hyperinsulinemia is a common symptom in obese and type 2 diabetic patients. Hepatocellular cancer has increased incidence and prevalence in obesity (31) . Compared with the general population, diabetic patients have an increased frequency of hepatitis C, which may contribute to prolonged insulin resistance and liver cancer (32) . As a growth factor, insulin is crucial in liver regeneration (33) , promotes the growth of the human hepatoma cell line PLC/PRF/5 (34) , and reverses the dexamethasone-induced inhibition of rat hepatoma-cell growth and cell-cycle traverse (35) . It has been reported that HepG2 cells have intact insulin signaling (36), so we selected HepG2 cells as a cell model to investigate the effects of insulin on Zbtb7A expression. We present evidence of a possible relationship between type 2 diabetes and hepatocarcinoma and our results imply that Zbtb7A might not only be a downstream target of insulin but also an effector of insulin in tumorigenesis.
In conclusion, the present study demonstrates that insulin enhances Zbtb7A expression via activation of the PI3K/AKT cascade and the transcription factor Sp1 in HepG2 cells. This is the first report concerning the regulation of Zbtb7A expression by insulin, which may have significant implications for the development of diabetes-associated carcinoma and provide insight into the importance of Zbtb7A in clinical treatment.
